ALS Stories of Hope_1.jpeg

Amyotrophic lateral sclerosis

Best reviews

2019: Cannabis in mouse models of ALS

Effects of cannabinoids in Amyotrophic Lateral Sclerosis (ALS) murine models: a systematic review and meta-analysis

https://pubmed.ncbi.nlm.nih.gov/30520038/

2016: A review of ALS and the cannabinoids

Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis?

https://www.ncbi.nlm.nih.gov/pubmed/28197175

2015: A book chapter by Dr. Pertwee

Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis

https://pubmed.ncbi.nlm.nih.gov/26408162/

2010: Cannabis & ALS

Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials

http://www.ncbi.nlm.nih.gov/pubmed/20439484

2008: The ECS & ALS

The endocannabinoid system in amyotrophic lateral sclerosis

https://pubmed.ncbi.nlm.nih.gov/18781981/

2001: Carter’s review of why cannabis might be helpful for ALS

Marijuana in the management of amyotrophic lateral sclerosis

https://www.ncbi.nlm.nih.gov/pubmed/11467101

Timeline of Research

2021: Former football player Steve Gleason, who has ALS, testified to Louisiana lawmakers about how medical marijuana saved him from a “downward spiral” of side effects from prescription medications

https://www.marijuanamoment.net/medical-marijuana-saved-former-nfl-player-from-downward-spiral-he-tells-louisiana-lawmakers/

2020: In humans with ALS, their blood levels of AEA, 2-AG & 2-OG were predictive of their disease state (66 patients)

Endocannabinoids and related lipids in serum from patients with amyotrophic lateral sclerosis

https://pubmed.ncbi.nlm.nih.gov/33094490/

2019: In humans with ALS, a combination of THC & CBD found helpful (32  patients in a retrospective mono-centric cohort study)

Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD)

https://www.ncbi.nlm.nih.gov/pubmed/31493784

2017: In tissue model of ALS, CBD changed genes related to ALS pathology, oxidative stress, mitochondrial dysfunction, and excitotoxicity

Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis

https://www.ncbi.nlm.nih.gov/pubmed/27714895

2017: A case study of using CBD for ALS

[Self-medication with cannabidiol oil in a patient with primary lateral sclerosis]

https://www.ncbi.nlm.nih.gov/pubmed/28397674

2014: In a mouse model of ALS, help seen for ALS with Sativex via upregulation of CB2

Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex(®) -like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis

https://www.ncbi.nlm.nih.gov/pubmed/24703394

2010: In a mouse model of ALS, CB1 receptors very sensitive for controlling glutamate and GABA levels

Abnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosis

https://www.ncbi.nlm.nih.gov/pubmed/19452308

2008: In a mouse model of ALS, evidence for changes in level of CB1 & AMPA receptors

Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity

https://www.ncbi.nlm.nih.gov/pubmed/18279310

2007: In a mouse model of ALS, CB2 agonist slowed degeneration and preserved motor function

The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset

https://www.ncbi.nlm.nih.gov/pubmed/17241118

2006: In human spinal cords, the glial cells activated in MS & ALS show more COX2, P2X7 & CB2 – agonists suggested as therapeutic

COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord

https://www.ncbi.nlm.nih.gov/pubmed/16512913

2006: In a mouse model of ALS, synthetic and genetic methods to increase endocannabinoid levels show help for ALS

Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice

https://www.ncbi.nlm.nih.gov/pubmed/16571781

2006: In a mouse model of ALS, a synthetic CB1 agonist delays disease progress

AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis

https://www.ncbi.nlm.nih.gov/pubmed/16781706

2005: In mice, CBN as a significant tool against ALS

Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival

https://www.ncbi.nlm.nih.gov/pubmed/16183560

2004: In mice, efficacy of THC to attenuate excitotoxic and oxidative cell damage

Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid

https://www.ncbi.nlm.nih.gov/pubmed/15204022

2004: A small survey of cannabis users found it might be helpful for ALS

Survey of cannabis use in patients with amyotrophic lateral sclerosis

https://www.ncbi.nlm.nih.gov/pubmed/15055508